Industry News

Healthcare Innovation or “Click Bait”?

With the rise of digital media and the appetite for instant information, news outlets are increasingly rushing to get their stories to consumers first, sacrificing accuracy for viewership. This trend is particularly dangerous in regards to healthcare advancements. Titles are often misleading, creating false expectations of a treatment or cure. Information on early stage Alzheimer’s and related dementia research is often publicized without the necessary qualification that further testing is need to validate these initial findings.

Explore further in the Pharmaceutical Market Europe (PME) article, and be aware of “fake news” in healthcare reporting.

Spotlight on Frontotempal Dementia (FTD)

When most people think of dementia, Alzheimer’s disease is the first disease that comes to mind. Few people have heard of FTD, but it is the most common type of dementia for people under the age of 60 and is equally as devastating as AD. CBS’s Bill Whitaker introduces us to two families living with FTD in this moving ’60 Minutes’ story.

Does your community care for people living with FTD? Let us know by emailing us here and to see how we can help provide important research opportunities to your community.


What’s Happening in the Alzheimer’s Research Field?

A New Type of Dementia is Identified

Scientists have recently recognized Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) as a dementia disease. As the name suggests, age is a factor in the disease; anywhere from 20 to 50% of people over the age of 80 will have brain changes related to LATE. And that percentage increases with higher age.

The disease affects a different part of the brain and typically progresses more slowly than AD, but shares similar symptoms to AD (impairment of memory, learning, and thinking) which commonly results in misdiagnosis of LATE as AD.

Read the CNN Health article here.

Read the researchers’ article published in the neurology journal BRAIN.

A Vision for AD at the Upcoming G20 Summit

In May, the second annual Alzheimer’s Asian Scientific Roundtable was convened in Tokyo, Japan. Eighty leaders in research, policymaking, and patient advocacy attended from around the world. Together they released a Consensus Statement and Research Framework that calls on Japanese Prime Minister Shinzo Abe to use his position at the helm of the G20 in 2019 to elevate the concerns of AD and dementia, and to lead the global response.

Read the UsAgainstAlzheimer’s press release here.

Read the full Consensus Statement and Research Framework here.

Reducing the Emotional Burden of Providing Care

Information from a recent NIH funded study shows that teaching caregivers to focus on positive emotions will reduce anxiety and depression.  Participants in the Northwestern Medicine intervention had a 7 percent drop in depression and 9 percent drop in anxiety compared to the control group. An additional study is planned to compare the facilitated version with a new self-guided version.

Read more about the study here.


 

Categories: Monthly Updates

Leave a Reply

Your email address will not be published. Required fields are marked *